Sorry, you need to enable JavaScript to visit this website.

VYNDAQEL® OR VYNDAMAX™ (tafamidis meglumine or tafamidis) Indications and Usage

1. INDICATIONS AND USAGE

VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No